Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma

被引：40

作者：

Ma, Brigette B. Y. ^{[1
]}

Chan, Anthony T. C. ^{[1
]}

机构：

[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2006年 / 6卷 / 03期

关键词：

5-azacitidine; cetuximab; concurrent chemoradiotherapy; plasma Epstein-Barr virus DNA; nasopharyngeal carcinoma;

D O I：

10.1586/14737140.6.3.383

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nasopharyngeal carcinoma (NPC) is endemic in Asia and is etiologically associated with the Epstein-Barr virus. Although radiotherapy can cure most patients with early-stage disease, those with advanced disease often develop recurrences following radiotherapy. The past decade has witnessed significant advances in the systemic treatment of advanced NPC. This article reviews the latest literature regarding: combined modality therapy for locoregionally advanced NPC; clinical trials of novel biologic and cytotoxic therapies for metastatic NPC; and disease monitoring with the plasma Epstein-Barr virus DNA assay.

引用

页码：383 / 394

页数：12

共 86 条

[1] Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma [J].